Irina Lambertz

Vlaams Instituut voor Biotechnologie — Belgium

Medicine · Health Sciences

11h-index1.2kcitations59works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(40), MicroRNA in disease regulation(11), Cancer, Hypoxia, and Metabolism(11), Cancer-related Molecular Pathways(10), Cancer-related molecular mechanisms research(8)

Publications59 total

Supplemental Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 12 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 9 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 9 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 13 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 12 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 13 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplementary Table 2 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Table 1 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Table 1 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Data from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Data from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
2023Open Access
Supplementary Figures 1-5 from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Frank Speleman(34), Katleen De Preter(29), Shana Claeys(28), Johannes H. Schulte(28), Candy Kumps(25), Tom Van Maerken(25), Geneviève Laureys(22), Sara De Brouwer(17), Nadine Van Roy(17), Els Janssens(17), Alan Van Goethem(17), Jean‐Christophe Marine(16), Anneleen Beckers(15), Jan Cools(13), Jorge Vialard(12), Sven Lindner(11), Marilena De Mariano(11), Jay Gibbons(11), Michaël Porcu(11), Piotr Zabrocki(11)